Literature DB >> 24846644

Accuracy of rapid oral HCV diagnostic test among a Saudi sample.

Suzan Ibrahim1, Safia Ali Al Attas, Ghada Anwar Mansour, Soliman Ouda, Hind Fallatah.   

Abstract

OBJECTIVES: The objective of this study was to investigate the accuracy of the OraQuick® rapid diagnostic test in the detection of hepatitis C virus (HCV) antibodies in oral fluid among a Saudi population sample.
DESIGN: A case-control cross-sectional study was conducted on 60 HCV-positive patients and 100 HCV-negative control subjects. PATIENTS AND METHODS: The HCV-positive patients were recruited from the Clinics of Infectious Diseases of King Abdulaziz University (KAU) Hospital, Jeddah, while the control group was collected from KAU, Faculty of Dentistry, including staff and students. The OraQuick® HCV rapid antibody test (OraSure Technologies, Inc. USA) utilized the oral fluid swab. Sensitivity and specificity for the test were calculated and correlated to the patients' viral load.
RESULTS: Out of the 60 PCR + ve patients, 53 (88.33 %) revealed a positive OraQuick test, whereas 7 (11.67 %) patients showed negative test, revealing 88.33 % sensitivity and 100 % specificity for detection of salivary HCV antibodies. Only PCR level was valuable in predicting the outcome of OraQuick test.
CONCLUSION: Using oral fluid for the detection of HCV antibodies could be a useful tool for epidemiological purposes and for field collection of samples in developing countries or in nonclinical settings by persons with minimal training. CLINICAL RELEVANCE: Millions of pilgrims visit Saudi Arabia during every year, many of whom are from countries where HCV infection is endemic; therefore, it will be very helpful to use a noninvasive, quick, simple, specific, and sensitive method for detection of HCV antibodies using oral fluid.

Entities:  

Mesh:

Year:  2014        PMID: 24846644     DOI: 10.1007/s00784-014-1261-y

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  27 in total

1.  The use of the OraSure collection device for hepatitis virus testing in health care settings.

Authors:  Sheila O Cameron; William F Carman
Journal:  J Clin Virol       Date:  2005-12       Impact factor: 3.168

Review 2.  Detection of HCV RNA in saliva of patients with hepatitis C virus infection by using a highly sensitive test.

Authors:  M Hermida; M C Ferreiro; S Barral; R Laredo; A Castro; P Diz Dios
Journal:  J Virol Methods       Date:  2002-03       Impact factor: 2.014

3.  Global burden of hepatitis C: considerations for healthcare providers in the United States.

Authors:  Francisco M Averhoff; Nancy Glass; Deborah Holtzman
Journal:  Clin Infect Dis       Date:  2012-07       Impact factor: 9.079

4.  Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus.

Authors:  Bryce D Smith; Jan Drobeniuc; Amy Jewett; Bernard M Branson; Richard S Garfein; Eyasu Teshale; Saleem Kamili; Cindy M Weinbaum
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

5.  Detection of hepatitis A antibodies by ELISA using saliva as clinical samples.

Authors:  I T Oba; A M Spina; C P Saraceni; M F Lemos; R Senhoras; R C Moreira; C F Granato
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2000 Jul-Aug       Impact factor: 1.846

6.  Detection of antibodies against hepatitis C virus in saliva: a marker of viral replication.

Authors:  S O Cameron; K S Wilson; T Good; J McMenamin; B McCarron; A Pithie; R Fox
Journal:  J Viral Hepat       Date:  1999-03       Impact factor: 3.728

7.  Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots.

Authors:  Ali Judd; John Parry; Matthew Hickman; Tamara McDonald; Laura Jordan; Kim Lewis; Marcela Contreras; Geoff Dusheiko; Graham Foster; Noël Gill; Katie Kemp; Janice Main; Iain Murray-Lyon; Mark Nelson
Journal:  J Med Virol       Date:  2003-09       Impact factor: 2.327

8.  Detection of hepatitis C virus antibodies in oral fluid specimens for prevalence studies.

Authors:  V González; E Martró; C Folch; A Esteve; L Matas; A Montoliu; J R Grífols; F Bolao; C Tural; R Muga; J V Parry; V Ausina; J Casabona
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11-20       Impact factor: 3.267

9.  Detection of replicative form of hepatitis C virus RNA in peripheral blood mononuclear cells.

Authors:  J T Wang; J C Sheu; J T Lin; T H Wang; D S Chen
Journal:  J Infect Dis       Date:  1992-11       Impact factor: 5.226

10.  Hepatitis C virus infections reported in Saudi Arabia over 11 years of surveillance.

Authors:  Tariq A Madani
Journal:  Ann Saudi Med       Date:  2007 May-Jun       Impact factor: 1.526

View more
  4 in total

1.  Comparative evaluation of three rapid immunochromatographic test assays with chemiluminescent microparticle immunoassay for the detection of hepatitis C virus antibody.

Authors:  Supriya Mahajan; Reshu Agarwal; Vaishali Rawat; Guresh Kumar; Manoj Kumar Sharma; Ekta Gupta
Journal:  Virusdisease       Date:  2019-07-24

Review 2.  Diagnostic accuracy of tests to detect Hepatitis C antibody: a meta-analysis and review of the literature.

Authors:  Weiming Tang; Wen Chen; Ali Amini; Debi Boeras; Jane Falconer; Helen Kelly; Rosanna Peeling; Olivia Varsaneux; Joseph D Tucker; Philippa Easterbrook
Journal:  BMC Infect Dis       Date:  2017-11-01       Impact factor: 3.090

3.  Can HIV service data be used for surveillance purposes?: a case study in Guangzhou, China.

Authors:  Weibin Cheng; Huifang Xu; Fei Zhong; Stephen Pan; Joseph D Tucker; Sharon Weir; Jinkou Zhao; Weiming Tang
Journal:  BMC Public Health       Date:  2018-11-19       Impact factor: 3.295

4.  A population-based screening for hepatitis C antibodies and active infection using a point-of-care test in a low prevalence area.

Authors:  Ângela Carvalho-Gomes; Almudena Cubells; Carmina Pallarés; Vanessa Hontangas; Isabel Conde; Tomasso Di Maira; Salvador Peiró; Gabriel Sanfélix-Gimeno; F Xavier López-Labrador; Marina Berenguer
Journal:  PLoS One       Date:  2020-02-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.